A Phase I Study of TQ-B3456 on Tolerance and Pharmacokinetics
Latest Information Update: 12 Apr 2022
Price :
$35 *
At a glance
- Drugs TQ B3456 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 29 Mar 2022 Status changed from recruiting to discontinued.
- 03 Dec 2018 New trial record